Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry researchers · Friday, March 29, 2024 · 699,676,577 Articles · 3+ Million Readers

RavenQuest BioMed Expands Geographical Production Footprint -- CFN Media

SEATTLE, June 19, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering RavenQuest BioMed Inc. (CSE:RQB) (RQB.CN) (CNSX:RQB) (OTCQB:RVVQF).

Canada’s upcoming legalization of recreational cannabis could put pressure on cannabis supply, according to a variety of sources, even as many licensed producers ramp up production capacity. Deloitte analysts project that the market could top C$22.6 billion over the coming years, driven by both domestic growth from recreational legalization and growing demand for export from the European Union and other countries around the world.

RavenQuest BioMed Inc. is well-positioned to capitalize on these trends with its four-pillar approach to the industry and rapidly growing production portfolio. After moving to acquire another late-stage applicant earlier this month, investors may want to take a closer look at the stock over the coming months.

Western Agripharma Acquisition

RavenQuest BioMed recently announced a binding letter of intent to acquire Western Agripharma Ltd. and a 15-acre parcel of land for 4,335,294 common shares at $0.85 per share, or roughly $3.7 million in consideration. Management intends to apply its proprietary grow methodologies - Orbital Gardens - to the facility to dramatically increase the grams-per-square-foot production and unlock significant value in the transaction.

Western Agripharma is a late-stage applicant to become a licensed producer under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). With a 125,000 purpose-built facility in British Columbia’s Sunshine Coast, Western Agripharma will have an annual production capacity of about 25,000 kilograms and increase RavenQuest BioMed’s total capacity to about 51,000 kilograms per year once everything is in operation.

In addition to the 125,000 sq. ft. facility, Western Agripharma also owns a 23.75 percent stake in Atlantic Cannabis Corp., which intends to build a 50,000 sq. ft. facility and holds an additional 120 acre property in early stage application on Nova Scotia’s Cape Breton Island. This opportunity represents a longer-term opportunity in the cannabis industry, but offers additional production capacity that is geographically diversified.

Building a Presence Across Canada

The move to acquire Western Agripharma - and part of Atlantic Cannabis Corp. - is part of the RavenQuest BioMed’s long-term plan to expand its geographic footprint throughout Canada. Once the deal is completed, the company will have state of the art licensed facilities in Ontario, Alberta, and British Columbia, which represent three of the most dynamic markets in Canada for the cannabis industry given their population sizes and usage patterns.

“This acquisition adds the important British Columbia market to our growing presence in key markets across Canada,” said RavenQuest BioMed CEO George Robinson. “RavenQuest will have state of the art licensed cannabis facilities in Ontario, Alberta and British Columbia ... The Western Agripharma facility will produce 25,000 kilograms annually, meaning RavenQuest’s planned projects will combine to produce 51,000 kilograms annually at build out.”

The acquisition strategy is also just one of the company’s four-pillar approach to the industry, which includes Indigenous People’s partnerships, investments in near-term cultivation, immediate revenue from management services, and ongoing research. Management has reported progress across all of these pillars over the past several quarters and the latest LOI to acquire a new late-stage applicant underscores these developments.

Looking Ahead

RavenQuest BioMed Inc. (CSE:RQB) represents a compelling investment opportunity in Canada’s burgeoning cannabis market. With its latest acquisition of a late-stage applicant, the company has both increased its planned production capacity and diversified its geographical footprint. These developments are only just the latest of many developments towards scaling up its four-pillar approach to the cannabis industry.

For more information, visit the company’s website or download their investor presentation.

Please follow the link to read the full article: http://www.cannabisfn.com/ravenquest-biomed-expands-geographical-production-footprint/

About CFN Media

CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Contact:
CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

Primary Logo

Powered by EIN News
Distribution channels: Healthcare & Pharmaceuticals Industry


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release